Critical reviews in oncology/hematology最新文献_第6页

The emerging HER2 landscape in colorectal cancer: the key to unveil the future treatment algorithm? 结直肠癌中新出现的 HER2 标志：揭示未来治疗算法的关键？

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-09-18 DOI: 10.1016/j.critrevonc.2024.104515

Jacopo Venturini , Giulia Massaro , Daniele Lavacchi , Daniele Rossini , Serena Pillozzi , Enrico Caliman , Elisa Pellegrini , Lorenzo Antonuzzo

{"title":"The emerging HER2 landscape in colorectal cancer: the key to unveil the future treatment algorithm?","authors":"Jacopo Venturini , Giulia Massaro , Daniele Lavacchi , Daniele Rossini , Serena Pillozzi , Enrico Caliman , Elisa Pellegrini , Lorenzo Antonuzzo","doi":"10.1016/j.critrevonc.2024.104515","DOIUrl":"10.1016/j.critrevonc.2024.104515","url":null,"abstract":"<div><div>Colorectal cancer (CRC) represents a global health threat, standing as the second leading cause of cancer-related death worldwide. Targeted therapies brought new hope for the metastatic stage, which historically bore a very poor prognosis. Human epidermal growth receptor 2 (HER2) overexpression concerns about 5 % of the metastatic CRC (mCRC) patients, including both gene amplifications and point mutations. Albeit its controversial prognostic role, preclinical and clinical data indicate HER2 as a negative predictive biomarker of response to anti-EGFR therapies. Tissue and plasma-based NGS testing, could permit a precise identification of this resistance mechanism both at baseline and during treatment, thus guiding decision-making. Furthermore, promising results come from completed and ongoing randomized trials, testing HER2 as an actionable target. In this review, we discuss the available evidence on HER2 targeting in advanced CRC, analyzing its possible future role in the treatment algorithm.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"204 ","pages":"Article 104515"},"PeriodicalIF":5.5,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1040842824002580/pdfft?md5=eab9df80d555f02399a513bf0b2e25d1&pid=1-s2.0-S1040842824002580-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142303484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A comprehensive review of current treatment modalities for leptomeningeal carcinomatosis in breast cancer 全面回顾当前治疗乳腺癌脑膜癌的方法

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-09-14 DOI: 10.1016/j.critrevonc.2024.104513

Charles D. Morris , Clare Humphrey , Patrick Dillon

引用次数: 0

The diagnostic accuracy of single-item scales in detecting fatigue in patients with cancer: A systematic review and meta-analysis 单项量表在检测癌症患者疲劳方面的诊断准确性：系统回顾与荟萃分析

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-09-14 DOI: 10.1016/j.critrevonc.2024.104496

Yi-An Lu , Yeu-Hui Chuang , Tsai-Wei Huang , Made Satya Nugraha Gautama

{"title":"The diagnostic accuracy of single-item scales in detecting fatigue in patients with cancer: A systematic review and meta-analysis","authors":"Yi-An Lu , Yeu-Hui Chuang , Tsai-Wei Huang , Made Satya Nugraha Gautama","doi":"10.1016/j.critrevonc.2024.104496","DOIUrl":"10.1016/j.critrevonc.2024.104496","url":null,"abstract":"<div><h3>Background</h3><p>Early detection of fatigue is crucial for cancer patients. Although single-item scales are convenient, their diagnostic accuracy remain unclear, and the variability across studies may affect generalizability. This systematic review and meta-analysis evaluates the diagnostic value of single-item fatigue detection scales.</p></div><div><h3>Methods</h3><p>We systematically searched CINAHL, Cochrane Library, Embase, and PubMed. Meta-analyses were conducted to calculate pooled sensitivity, specificity, likelihood ratios, predictive values, and diagnostic odds ratios (DOR). We also calculated the area under a hierarchical summary receiver operating characteristic curve. Subgroup analyses were performed to address heterogeneity. All analyses were done R (version 4.3.1). The study registered in PROSPERO (CRD42023457658).</p></div><div><h3>Results</h3><p>Eleven studies involving 3509 participants were included. Pooled results revealed a sensitivity of 0.89 (95 % CI: 0.82–0.93), specificity of 0.72 (95 % CI: 0.63–0.80), DOR of 19.95 (95 % CI: 10.47–38.04), and an AUC of 0.90 (95 % CI: 0.89–0.91). Moderate to high heterogeneity was observed, influenced by variations in cancer types, study designs, and gold standard references.</p></div><div><h3>Conclusion</h3><p>Single-item fatigue scales demonstrate commendable diagnostic accuracy, comparable to multidimensional scales. Despite study variability, they are effective for routine clinical use to detect and manage fatigue in cancer patients. Future research should focus on standardizing assessment criteria and optimizing the balance between simplicity and diagnostic precision.</p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"204 ","pages":"Article 104496"},"PeriodicalIF":5.5,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142274102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Insights into the molecular alterations of PLAG1 and HMGA2 associated with malignant phenotype acquisition in pleomorphic adenoma 洞察多形性腺瘤恶性表型获得过程中 PLAG1 和 HMGA2 的分子变化。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-09-13 DOI: 10.1016/j.critrevonc.2024.104494

Reydson Alcides de Lima-Souza , Gustavo de Souza Vieira , Talita de Carvalho Kimura , João Figueira Scarini , Luccas Lavareze , Tayná Figueiredo Maciel , Moisés Willian Aparecido Gonçalves , Erika Said Abu Egal , Albina Altemani , Fernanda Viviane Mariano

{"title":"Insights into the molecular alterations of PLAG1 and HMGA2 associated with malignant phenotype acquisition in pleomorphic adenoma","authors":"Reydson Alcides de Lima-Souza , Gustavo de Souza Vieira , Talita de Carvalho Kimura , João Figueira Scarini , Luccas Lavareze , Tayná Figueiredo Maciel , Moisés Willian Aparecido Gonçalves , Erika Said Abu Egal , Albina Altemani , Fernanda Viviane Mariano","doi":"10.1016/j.critrevonc.2024.104494","DOIUrl":"10.1016/j.critrevonc.2024.104494","url":null,"abstract":"<div><div>Pleomorphic adenoma (PA) is the most common neoplasm of the salivary gland, presenting with a variety of histological features. In some cases, PA can undergo malignant transformation to carcinoma ex pleomorphic adenoma (CXPA). The transition from PA to CXPA is associated with complex molecular alterations, particularly involving the <em>pleomorphic adenoma gene 1</em> (<em>PLAG1</em>) and <em>high mobility group protein gene</em> (<em>HMGA2</em>). This review investigates the molecular alterations of PLAG1 and HMGA2 in all domains in the malignant transformation of PA. Our analysis highlights that these markers are key alterations in the etiopathogenesis of PA and CXPA, with gene fusion and amplification being frequently reported mechanisms. Although the exact role of PLAG1 and HMGA2 in the oncogenic process remains unclear, further studies on the HMGA2 and PLAG1, are needed particularly in HMGA2-PLAG1-IGF2 which is proving to be a potential pathway for the development of clinically applicable therapies, especially for CXPA management.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"204 ","pages":"Article 104494"},"PeriodicalIF":5.5,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142303481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeted therapy with polymeric nanoparticles in PBRM1-mutant biliary tract cancers: Harnessing DNA damage repair mechanisms 聚合纳米粒子对 PBRM1 突变胆道癌的靶向治疗：利用 DNA 损伤修复机制。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-09-08 DOI: 10.1016/j.critrevonc.2024.104505

Hrushikesh Wagh , Sankha Bhattacharya

引用次数: 0

Colorectal cancer with BRAF V600E mutation: Trends in immune checkpoint inhibitor treatment BRAF V600E 基因突变的结直肠癌：免疫检查点抑制剂的治疗趋势。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-09-07 DOI: 10.1016/j.critrevonc.2024.104497

Mengling Liu , Qing Liu , Keshu Hu , Yu Dong , Xun Sun , Zhiguo Zou , Dingkun Ji , Tianshu Liu , Yiyi Yu

{"title":"Colorectal cancer with BRAF V600E mutation: Trends in immune checkpoint inhibitor treatment","authors":"Mengling Liu , Qing Liu , Keshu Hu , Yu Dong , Xun Sun , Zhiguo Zou , Dingkun Ji , Tianshu Liu , Yiyi Yu","doi":"10.1016/j.critrevonc.2024.104497","DOIUrl":"10.1016/j.critrevonc.2024.104497","url":null,"abstract":"<div><p>Colorectal cancer (CRC) with <em>BRAF</em> V600E mutation presents a formidable scientific and clinical challenge due to its aggressive nature and poor response to standard therapeutic approaches. <em>BRAF</em> V600E mutation-induced conspicuous activation of the MAPK pathway contributes to the relentless tumor progression. Nevertheless, the efficacy of multi-targeted MAPK pathway inhibition remains suboptimal in clinical practice. Patients with high microsatellite instability (MSI-H) have shown favorable results with immune checkpoint inhibitors (ICIs). The combination of the MAPK pathway inhibition with ICIs has recently emerged as a promising regimen to improve clinical outcomes in the microsatellite stable (MSS) subgroup of <em>BRAF</em> V600E-mutant metastatic CRC patients. In this review, we elucidate the unique tumor biology of <em>BRAF</em> V600E-mutant CRC, with a particular focus on the immune features underlying the rationale for ICI treatments in the MSI-H and MSS subpopulations, then highlight the trends in clinical trials of the ICI therapy for <em>BRAF</em> V600E-mutant metastatic CRC.</p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"204 ","pages":"Article 104497"},"PeriodicalIF":5.5,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142156856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Proton therapy for adult-type diffuse glioma: A systematic review 质子治疗成人型弥漫性胶质瘤：系统综述。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-09-07 DOI: 10.1016/j.critrevonc.2024.104501

Nicolas Goliot , Selim Mohssine , Dinu Stefan , Arthur Leclerc , Evelyne Emery , Jeanne Riverain , Fernand Missohou , Julien Geffrelot , William Kao , Samuel Valable , Jacques Balosso , Paul Lesueur

{"title":"Proton therapy for adult-type diffuse glioma: A systematic review","authors":"Nicolas Goliot , Selim Mohssine , Dinu Stefan , Arthur Leclerc , Evelyne Emery , Jeanne Riverain , Fernand Missohou , Julien Geffrelot , William Kao , Samuel Valable , Jacques Balosso , Paul Lesueur","doi":"10.1016/j.critrevonc.2024.104501","DOIUrl":"10.1016/j.critrevonc.2024.104501","url":null,"abstract":"<div><h3>Background</h3><p>We conducted a systematic review to evaluate outcomes and toxicities associated with proton therapy in the treatment of adult-type diffuse glioma.</p></div><div><h3>Methods</h3><p>Following PRISMA guidelines, we searched PubMed for both prospective and retrospective studies on proton therapy for adult diffuse gliomas, including IDH-mutated gliomas WHO grade 2-3 and glioblastomas. Survival and toxicity outcomes were reported separately for these glioma types.</p></div><div><h3>Results</h3><p>Twelve studies from 2013 to 2023 were selected, comprising 3 prospective and 9 retrospective studies. The analysis covered 570 patients with WHO grade 2-3 gliomas and 240 patients with glioblastoma or WHO grade 4 gliomas. Proton therapy was found to be comparable to conventional radiotherapy in terms of survival outcomes. Its main advantage is the ability to minimize radiation exposure to healthy tissues.</p></div><div><h3>Discussion</h3><p>Proton therapy offers comparable survival outcomes to conventional radiotherapy for adult diffuse gliomas and may enhance treatment tolerance, especially regarding neurocognitive function. A major limitation of this review is the predominance of retrospective studies. Future research should ensure rigorous patient selection and adhere to the latest WHO 2021 classification</p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"204 ","pages":"Article 104501"},"PeriodicalIF":5.5,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142210597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The potential of circulating cell-free RNA in CNS tumor diagnosis and monitoring: A liquid biopsy approach 循环游离细胞 RNA 在中枢神经系统肿瘤诊断和监测中的潜力：液体活检方法

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-09-07 DOI: 10.1016/j.critrevonc.2024.104504

Carlos Pilotto Heming , Veronica Aran

{"title":"The potential of circulating cell-free RNA in CNS tumor diagnosis and monitoring: A liquid biopsy approach","authors":"Carlos Pilotto Heming , Veronica Aran","doi":"10.1016/j.critrevonc.2024.104504","DOIUrl":"10.1016/j.critrevonc.2024.104504","url":null,"abstract":"<div><p>Early detection of malignancies, through regular cancer screening, has already proven to have potential to increase survival rates. Yet current screening methods rely on invasive, expensive tissue sampling that has hampered widespread use. Liquid biopsy is noninvasive and represents a potential approach to precision oncology, based on molecular profiling of body fluids. Among these, circulating cell-free RNA (cfRNA) has gained attention due to its diverse composition and potential as a sensitive biomarker. This review provides an overview of the processes of cfRNA delivery into the bloodstream and the role of cfRNA detection in the diagnosis of central nervous system (CNS) tumors. Different types of cfRNAs such as microRNAs (miRNAs), long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs) have been recognized as potential biomarkers in CNS tumors. These molecules exhibit differential expression patterns in the plasma, cerebrospinalfluid (CSF) and urine of patients with CNS tumors, providing information for diagnosing the disease, predicting outcomes, and assessing treatment effectiveness. Few clinical trials are currently exploring the use of liquid biopsy for detecting and monitoring CNS tumors. Despite obstacles like sample standardization and data analysis, cfRNA shows promise as a tool in the diagnosis and management of CNS tumors, offering opportunities for early detection, personalized therapy, and improved patient outcomes.</p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"204 ","pages":"Article 104504"},"PeriodicalIF":5.5,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142210596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epigenetic-modifying agents: The potential game changers in the treatment of hematologic malignancies 表观遗传修饰剂：治疗血液恶性肿瘤的潜在变革者。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-09-06 DOI: 10.1016/j.critrevonc.2024.104498

Tahereh Hojjatipour , Mina Ajeli , Amirhosein Maali , Mehdi Azad

引用次数: 0

Management of peripheral neuropathy associated with brentuximab vedotin in the frontline treatment of classical Hodgkin lymphoma 在经典霍奇金淋巴瘤的一线治疗中处理与 Brentuximab Vedotin 相关的外周神经病。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-09-06 DOI: 10.1016/j.critrevonc.2024.104499

Jeremy S. Abramson , Robert Stuver , Alex Herrera , Emily Patterson , Yi-Ping Wen , Alison Moskowitz

引用次数: 0